HIV / AIDS in the News

Researchers see dramatic drop in HIV-infected immune cells in patient after cancer treatment received - European AIDS Treatment Group

 

Gilead’s experimental HIV treatment meets main goal in late-stage trial - WTVB

 

Gilead’s investigational single-tablet regimen of bictegravir and lenacapavir for HIV treatment meets primary endpoint in Phase 3 ARTISTRY-2 trial - European AIDS Treatment Group

 

Choose U ambassadors share lived experiences with HIV, personal reflections and insights - Dallas Voice

 

Center for Biostatistics in AIDS Research (CBAR): 2025 Highlights - Harvard T.H. Chan School of Public Health

 

Dramatic drop in HIV-infected immune cells occurs in patient who received cancer treatment - Medical Xpress

 

A testing paradox: Rising sexually transmitted infections cases may mask actual decline in infections - Medical Xpress

 

Gilead posts second Phase 3 win for new HIV-fighting drug regimen - Endpoints News

 

Achieving lasting remission for HIV - Caledonian Record

 

Gilead’s HIV ART combo deemed non-inferior in second Phase III trial - Clinical Trials Arena

 

Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Meets Primary Endpoint in Phase 3 Study - Contagion Live

 

Gilead's experimental HIV treatment non-inferior to blockbuster drug in trial - Reuters

 

Gilead Sciences: Strategic Expansion in HIV Treatment Bolsters Buy Rating - TipRanks

 

Gilead Sciences Reports Positive Phase 3 ARTISTRY-2 HIV Trial Results - Nasdaq

 

How quitting nicotine can benefit people living with HIV - Truth Initiative

 

Panama warns om geople diagnosed with HIV/AIDS - plenglish.com

 

Gilead Yeztugo HIV combo pill meets goal in second phase 3 trial - Seeking Alpha

 

Ryan White never got to go to IU. A new sculpture ensures he will - The Herald-Times

 

Gilead’s experimental HIV treatment meets main goal in late-stage trial - TradingView — Track All Markets

 

Gilead’s experimental HIV treatment meets main goal in late-stage trial - Yahoo

 

Gilead’s experimental HIV treatment meets main goal in late-stage trial - TradingView — Track All Markets

 

POZ Poll: Nationwide, new HIV cases dropped 19% between 2010 to 2022, but New York City just reported a 5.4% uptick from 2023 to 2024. How do you think overall U.S. rates will change in 2026? - POZ

 

Gilead (Nasdaq: GILD) to base HIV filings on Phase 3 ARTISTRY BIC/LEN trials - Stock Titan

 

Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial - Yahoo Finance

 

Enhancing HIV Prevention for Recently Released Inmates - Bioengineer.org

 

HIV Ireland’s dangerous message - Gript

 

Blazing a new path for HIV prevention: A discussion with Dr. Moupali Das - Yale School of Public Health

 

Legendary actor makes eye-opening HIV claim - Yahoo

 

Legendary actor makes eye-opening HIV claim - PennLive.com

 

Does India’s HIV success story overlook its poorest state? - South China Morning Post